TAILORx

TAILORx: an update incl 12-year event rates in woman with ER+ lymph node-negative breast cancer 5:18
TAILORx: an update incl 12-year event rates in woman with ER+ lymph node-negative breast cancer
Joseph Sparano • 7 Dec 2022
Racial disparities in breast cancer and metastasis and possible contributing biological factors 4:39
Racial disparities in breast cancer and metastasis and possible contributing biological factors
Joseph Sparano • 7 Dec 2022
Molecular profiling in early breast cancer 8:22
Molecular profiling in early breast cancer
Christos Sotiriou • 10 May 2021
Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer? 3:23
Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer?
Hope Rugo • 26 Mar 2021
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease 16:13
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease
Beat Thürlimann et al. • 22 Mar 2021
Time for change: introducing genomic predictors in ER+ breast cancer 3:11
Time for change: introducing genomic predictors in ER+ breast cancer
Martine Piccart • 23 Mar 2021
Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER 4:13
Genomic predictors for treatment selection in ER+ breast cancer: TAILORx, MINDACT, and RxPONDER
Martine Piccart • 23 Mar 2021
SABCS 2020: monarchE, PENELOPE-B, TAILORx & ASCENT 2:16
SABCS 2020: monarchE, PENELOPE-B, TAILORx & ASCENT
Matteo Lambertini • 9 Dec 2020
Trial updates in breast cancer from ASCO: TAILORx, PAKT, MONARCH 2 & MONALEESA-3 2:45
Trial updates in breast cancer from ASCO: TAILORx, PAKT, MONARCH 2 & MONALEESA-3
Robert Coleman • 1 Jun 2018
Breast cancer: new advances in personalized medicine and therapeutics 3:13
Breast cancer: new advances in personalized medicine and therapeutics
Howard Burris • 1 Jun 2018
The content of VJOncology is intended for healthcare professionals